We really cannot say whether chicken by any other name would smell as sweet or even as chickeny. While we do not compare ourselves to the Bard, we can say that cultivated chicken meat cannot be sold in Florida to allow any such olfactory comparison there. The manufacturer of just such a product challenged the
Standing
Same Rule, Different Setting: Litigants Cannot Usurp the FDA’s Authority

Today’s opinion, In re SoClean, Inc., Mktg., Sales Pracs., & Prods. Liab. Litig., No. 22-MC-00152-JFC, 2025 WL 974258 (Sp. Mstr. W.D. Pa. Mar. 20, 2025), involves a lot of case-specific discussion with little applicability to the broader readership of the Blog. But it also contains some general observations regarding invading the province of the FDA that are “so fresh and so clean” (if this litigation name takes you back, as it does us, to circa 2000 Outkast).Continue Reading Same Rule, Different Setting: Litigants Cannot Usurp the FDA’s Authority
Notorious Medicare Secondary Payer Plaintiffs Bounced Again

The MSP plaintiffs are at it again, and without success this time around. In MSP Recovery Claims Series LLC v. Pfizer Inc., 2025 U.S. Dist. LEXIS 38647 (D.D.C. Mar. 4, 2025), the group of law firms formed to file lawsuits under the Medicare Secondary Payer Act (hence the “MSP” in the various plaintiffs’ names)…
Collateral Litigation As A Deterrent Of Bogus Research?

From its start, the Blog has railed against certain expansions of traditional product liability that could have negative impacts on scientific progress and the availability of good medical products. Innovator liability, first described in Conte back in 2008, is a good example of a bad idea. Its offspring, the so-called duty to innovate…
Vague Testing Allegations Not Enough to Find Standing

Just last week we blogged about our disappointment over the Third Circuit’s resurrection of a “benefit of the bargain theory” of standing in Huertas v. Bayer US LLC, 120 F.4th 1169 (3d Cir. 2024). But we also recognized that Huertas had a silver lining that defendants could still use to challenge standing—by challenging the…
Money for Nothing? In an About Face, This Time the Third Circuit Said “Yes”

In 2018, our blogpost on In re Johnson & Johnson Talcum Powder Products Marketing, Sales Practices & Liability Litigation, 903 F.3d 278 (3d Cir. 2018), was entitled “Money For Nothing? No Standing This Time in the Third Circuit.” There, it appeared that the Third Circuit had drawn an eminently reasonable bright line disallowing no-injury…
Class Complaint Fails in OTC Drug MDL

When it comes to MDLs that concern a bunch of cases about a drug or device, they typically have a name like “In re [name of product(s)] Product Liability Litigation” or “In re [name of product(s) Marketing and Sales Practices Litigation.” In theory, the first group of MDLs involves, shockingly, product…
Drowsy Cold Medicine Consumer Fraud Case Sleepwalks Past Preemption

Long ago, a senior partner told us that clear writing flows from clear thinking. That might be so, but clear thinking and clear writing do not necessarily produce the correct result. For example, you’d have a tough time finding a legal opinion written more clearly than Calchi v. Topco Assocs., LLC, 2024 U.S. Dist.
A Unanimous Supreme Court Sits Down A Hippo

Standing should not be a political issue. Ensuring that someone who initiates a lawsuit has enough of a connection to the alleged harm for which they seek redress from a court is a key part of the broader constitutional concept of justiciability. Because federal courts are courts of limited jurisdiction, they cannot decide just any…
A New Version of the One-Two Punch: Standing and Preemption

Oh, so many years ago we started calling cases that prevent innovator liability and preempt generic liability the “one-two punch.” But really any decision that strikes a substantive blow and follows it up with a preemption jab is OK in our books. And that is just what happened in Harris v. Medtronic Inc., 2024 WL…